Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease [1]

Archives of Disease in Childhood

Volumn 90, Issue 10, 2005, Pages 1096-1097

  Miura, M ^a   Ohki, H ^a   Yoshiba, S ^a   Ueda, H ^a   Sugaya, A ^a   Satoh, M ^a   Yamagishi, H ^b  

^a TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEPARIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE;

BODY TEMPERATURE; CLINICAL ARTICLE; DRUG PULSE THERAPY; EMBOLISM; GLUCOSE BLOOD LEVEL; HEART RATE VARIABILITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTHERMIA; LETTER; MUCOCUTANEOUS LYMPH NODE SYNDROME; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SIDE EFFECT; SINUS BRADYCARDIA; SYSTOLIC BLOOD PRESSURE;

ANTICOAGULANTS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HEPARIN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; METHYLPREDNISOLONE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PULSE THERAPY, DRUG;

EID: 26044441696     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2004.062299     Document Type: Letter

References (4)

1. Fujimoto S, Kondoh H, Yamamoto Y, et al. Holter electrocardiogram monitoring in nephrotic patients during methylprednisolone pulse therapy. Am J Nephrol 1990;10:231-6.
2. Garrett R, Paulus H. Complications of intravenous methylprednisolone pulse therapy. Arthritis Rheum 1980;23:677.
3. Miura M, Ohki H, Tsuchihashi T, et al. Coronary risk factors in Kawasaki disease treated with additional gamma-globulin. Arch Dis Child 2004;89:776-80.
4. Shulman ST. Is there a role for corticosteroids in Kawasaki disease? J Pediatr 2003;142:601-3.